Clinical Trial Supply Chains Are Entering The Era Of Predictive Risk Management

By Laura Hay, senior director of global program management, Trax Group | 2025 Winner, everywoman Customer/Passenger (Leader) Award

When organizations think about clinical trial supply chain risk, they often focus on how effectively they can respond once a disruption occurs. A shipment is delayed. Enrollment patterns change. Manufacturing timelines shift. A geopolitical event impacts transportation routes. Teams quickly mobilize to identify solutions and protect patient dosing schedules.

While rapid response will always be an essential capability, the future of clinical trial supply chain management is moving toward something more proactive: the ability to identify risk before it becomes a disruption.

Predictive risk management represents a fundamental shift in how organizations approach clinical supply planning. Instead of waiting for shortages, delays, or inventory challenges to appear, supply teams are beginning to leverage data, analytics, and connected systems to recognize early warning signals and take action sooner. This shift is becoming increasingly important as clinical trials become more complex. Global studies now involve multiple regions, specialized therapies, evolving enrollment patterns, and supply networks that must operate across changing regulatory, transportation, and geopolitical environments.

The challenge is no longer simply managing inventory. The challenge is understanding what future conditions may impact supply availability and making decisions before those risks affect patients, sites, or timelines.

Traditional supply planning models have historically relied on forecasts, historical demand patterns, and scheduled reviews. While these tools remain important, they are often limited because they provide visibility into what has already happened rather than what is likely to happen next.

By the time a shortage appears in a report, a depot reaches a critical inventory threshold, or a site requests an emergency shipment, teams may already be operating with fewer options.

Predictive risk management changes the question organizations are asking. Instead of asking, “What caused this supply issue?” teams can begin asking, “What signals are showing us that this risk may develop?”

These signals may come from multiple sources across the clinical supply ecosystem, including:

• enrollment velocity and changes in patient recruitment trends
• site activation timelines and regional trial performance
• RTSM/IRT demand signals compared with actual inventory positions
• manufacturing schedules and packaging capacity
• transportation conditions and logistics performance
• temperature monitoring and cold chain risk indicators
• weather events, geopolitical disruptions, and regulatory changes.

Individually, these signals may appear minor. However, when analyzed together, they can provide valuable insight into potential risks before they become operational challenges.

For example, a clinical trial may appear to have sufficient inventory based on current forecasts. However, if enrollment accelerates in a specific region, randomization rates increase, and depot inventory begins declining faster than expected, the combined signals may indicate a future supply constraint.

The organization may still have enough product today. The question becomes whether it will have enough supply to support tomorrow’s demand.

Enrollment variability is one of the clearest examples of why predictive intelligence is becoming essential in clinical trial supply. Clinical trials rarely progress exactly as planned. Recruitment may accelerate, enrollment may shift between regions, or site performance may change throughout the study life cycle. Each of these factors can significantly impact packaging requirements, inventory allocation, depot strategy, and transportation planning.

Without predictive visibility, organizations are often forced into reactive decisions such as expedited shipments, emergency packaging activities, or last-minute inventory transfers. These actions may protect immediate patient needs, but they can also increase costs, create inefficiencies, and reduce operational flexibility. Predictive supply planning allows teams to recognize these shifts earlier and adjust before pressure builds. The same principle applies to external disruptions.

Clinical supply chains are no longer influenced only by internal operational decisions. Weather events, geopolitical instability, transportation constraints, and regulatory changes can quickly create downstream impacts across global trial networks.

A delay at a manufacturing facility can affect multiple regions. A transportation disruption can impact temperature-sensitive therapies. A regulatory change can delay product release.

Organizations that rely only on reactive processes often find themselves solving problems after they occur. Organizations using predictive approaches can evaluate risk earlier, adjust inventory positioning, explore alternative logistics options, and make informed decisions before disruption reaches the patient level. Artificial intelligence and advanced analytics are helping accelerate this transformation.

The value of AI is not simply automating existing processes. Its greatest potential is the ability to analyze large volumes of data, identify patterns, and uncover relationships that may not be immediately visible through traditional reporting.

AI-driven predictive models can help supply teams:

• identify emerging inventory risks
• improve demand forecasting accuracy
• detect changes in enrollment behavior
• prioritize supply chain exceptions
• support proactive decision-making.

However, technology alone does not create predictive supply chains.

The foundation remains trusted data, connected systems, and strong operational processes. Without reliable information flowing across RTSM/IRT systems, ERP platforms, logistics networks, and supply planning tools, organizations cannot fully benefit from advanced analytics.

The most successful clinical supply organizations will not simply be those with the most technology. They will be the ones that know how to turn information into action.

Predictive risk management allows teams to move beyond reacting to disruption and toward anticipating change. It creates an opportunity to improve efficiency, reduce waste, strengthen resilience, and ultimately provide greater confidence that patients will receive the therapies they need when they need them.

In today’s clinical trial environment, the ability to predict risk is no longer a future capability. It is becoming a competitive advantage.

About The Author:

Laura Hay is a global supply chain leader specializing in program management, customer success, and account strategy. She has a proven track record of leading cross-functional teams to deliver complex, high-impact initiatives on time and within budget. Laura is known for building strong stakeholder relationships, driving operational excellence, and managing multimillion-dollar programs. She is passionate about connecting people, processes, and technology to build scalable, resilient supply chain solutions that deliver measurable business impact.